Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

NASDAQ:NERV opened at $2.68 on Wednesday. The firm has a market cap of $18.73 million, a price-to-earnings ratio of -6.09 and a beta of 0.11. The firm’s 50-day simple moving average is $2.21 and its 200 day simple moving average is $2.54. Minerva Neurosciences has a 52 week low of $2.03 and a 52 week high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.